Our Science
Our Story
News
Connect
Globe Newswire
August 1, 2024
Featured article
Read More
May 18, 2021
In The News
BioCentury
Lyell spinout Outpace leverages de novo proteins to control cell and gene therapies
READ MORE
DOWNLOAD
April 5, 2021
Forbes
Outpace Bio raises $30 Million to design next generation cell therapies
March 31, 2021
Public Relations
Creating next generation smart cell therapies: Outpace Bio receives $30 million in Series A funding led by ARTIS Ventures and Lyell Immunopharma Inc
PR
March 21, 2021
Endpoints News
A pair of Lyell founders look to shift the cell therapy paradigm — and they've got $30M to get their plan off the ground
1
All
Publications
August 2, 2023
GeekWire
Seattle startups move into growing science cluster in South Lake Union
July 10, 2023
How AI is changing the way scientists engineer drugs, biosensors, enzymes and more
May 26, 2023
Outpace Bio expands cell therapy R&D, nets research collaborations in Seattle
May 11, 2023
Keeping up with the protein designers
June 28, 2022
Biotech startups join AWS and other partners in open-source project to help design new proteins
February 21, 2022
Fred Hutch Cancer Center
Red Light, Green Light: Precise cell targeting with Co-LOCKR
May 4, 2023
Outpace Bio, a leader in protein design for cell therapy, strengthens executive leadership team with key appointments
March 23, 2023
Outpace Bio, a leader in protein design & cell engineering, adds Bahija Jallal to Board of Directors
April 7, 2024
American Association for Cancer Research (AACR)
In vitro modeling of antigen-driven exhaustion in human CAR T cells
"Development of tumor-restricted IL-12 with antigen-dependent expression and localized IL-12 activity"
OPB-101: An optimized mesothelin-specific CAR T cell product expressing CD8-targeted IL-2/15 and engineered to resist T cell exhaustion
November 3, 2023
Society for Immunotherapy of Cancer (SITC)
Protein design and inducible expression allow context-dependent, localized IL-12 activity to enhance solid tumor T cell therapies
October 9, 2023
Cancer Cell
Building smart CAR T cell therapies: The path to overcome current challenges
August 1, 2023
American Society for Gene & Cell Therapy (ASGCT)
OutSmart™ IL-2/15 Safely Stimulates CAR T Proliferation and Persistence in the Tumor while Limiting Regulatory T Cell Activation
The Outpace Press Kit is designed to help journalists research Outpace. Please contact our communications team if you need more information or to schedule an interview.